Exact Sciences (EXAS) to Release Quarterly Earnings on Wednesday

Exact Sciences (NASDAQ:EXAS) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.26. The company had revenue of $646.89 million during the quarter, compared to analysts’ expectations of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The business’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.72) EPS. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $59.35 on Wednesday. The firm has a 50 day moving average of $63.40 and a 200-day moving average of $64.89. The stock has a market capitalization of $10.91 billion, a PE ratio of -52.06 and a beta of 1.25. The company has a current ratio of 2.32, a quick ratio of 2.07 and a debt-to-equity ratio of 0.74. Exact Sciences has a 12 month low of $56.05 and a 12 month high of $100.77.

Insider Activity at Exact Sciences

In related news, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now owns 73,787 shares in the company, valued at approximately $5,165,090. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the company’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now owns 73,787 shares in the company, valued at $5,165,090. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kevin T. Conroy sold 14,791 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $908,611.13. Following the transaction, the chief executive officer now owns 1,224,357 shares in the company, valued at approximately $75,212,250.51. The disclosure for this sale can be found here. Insiders have sold 69,113 shares of company stock worth $4,165,273 in the last quarter. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Benchmark upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price objective for the company in a research report on Tuesday, January 2nd. Citigroup reissued a “buy” rating and set a $100.00 target price on shares of Exact Sciences in a report on Wednesday, April 3rd. Canaccord Genuity Group reduced their target price on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Finally, William Blair reissued an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 22nd. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $97.44.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.